Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114188 | 0.75 | MAPT (0.38) | — | |
| SCHEMBL16971392 | 0.73 | FLT3 (0.33) | — | |
| SCHEMBL2721185 | 0.70 | KCNH2 (0.33) | — | |
| SCHEMBL2762738 | 0.69 | MAPT (0.33) | — | |
| SCHEMBL30225249 | 0.67 | NOS3 (0.36) | — | |
| SCHEMBL1417302 | 0.67 | CYP2D6 (0.42) | TSHR | |
| SCHEMBL14120403 | 0.67 | — | — | |
| SCHEMBL19434945 | 0.67 | — | — | |
| SCHEMBL181124 | 0.67 | TLR8 (0.34) | CYP1A2 | |
| SCHEMBL22324130 | 0.67 | PDE4A (0.37) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531498-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-9181238-B2 | N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG | 2013-06-06 | — | — | US | disclosed |
| EP-2531498-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-12-12 | — | — | EP | disclosed |
| US-8026243-B2 | [4,5′]Bipyrimidinyl-6,4′-diamine derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | disclosed |
| WO-2011097526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-11 | — | — | WO | disclosed |
| EP-2044036-B1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2011-05-04 | — | — | EP | disclosed |
| US-20100234376-A1 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors | NOVARTIS AG | 2010-09-16 | — | — | US | disclosed |
| EP-2044036-A1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008747-A1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234376-A1 | [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors | FGFR3, ERBB2, ERBB4 | CYP1A2 3049/4885TSHR 4043/4885 |
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | RAF1, BRAF, ARAF | CYP1A2 3240/4885TSHR 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.